|
Kochetkov A.I., Shatalova N.A., Klepikova M.V., Filippova T.V., Ostroumova O.D.
More on the neuroprotectory therapy evidential base: focus at ethylmethyl hydroxypyridine succinate
|
№8 / 2023
|
|
Zakharov V.V., Ostroumova O.D., Kochetkov A.I., Klepikova M.V., Fedin A.I.
International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension
|
№1 / 2023
|
|
Maltseva I.V., Sheremetyeva I.I., Kotovschikova E.F., Stroganov A.E., Lukinov V.L.
Chronic brain ischemia in youthful age persons with undifferentiated connective tissue dysplasia
|
№10 / 2022
|
|
Kamchatnov P.R., Cheremin R.A., Skipetrova L.A., Chugunov A.V.
Cognitive disorders of vascular genesis in the practice of a therapist
|
№9 / 2022
|
|
Eliseeva l.N., Kartashova S.V.
Mexidol® and mexidol® forte 250 in consecutive therapy of cognitive disorders in comorbid patients with joint pathology on the background of arterial hypertension and ischemic heart disease
|
№6 / 2020
|
Русский
